FUNDRAISING FOR A CURE
Donating is simple, fast and totally secure. Your details are safe with us and we will never sell them

A revolutionary new cancer treatment that targets pancreatic tumours with radioactive micro-particles smaller than the width of a human hair has been used in the UK for the first time outside of a clinical trial.
Known as OncoSil, it is a form of brachytherapy – internal radiotherapy – which uses smallmicroparticles to deliver a high dose of radiation directly into the site of a tumour.
The treatment, currently only available privately, was carried out in Southampton.
The procedure works by injecting tiny radioactive phosphorous-32 microparticles, measuring just 28–32 micrometres in diameter, directly into the tumour via endoscopic ultrasound.
Once implanted, the microparticles remain in the tumour and release radiation over several weeks to target cancer cells while limiting exposure to surrounding healthy tissue.
Pancreatic cancer remains one of the most difficult cancers to treat.
Around 30 per cent of patients are diagnosed with locally advanced disease that cannot be surgically removed, leaving limited treatment options.
Estimates suggest that several thousand patients in the UK could be eligible for this type of targeted internal radiotherapy every year.
The procedure in Southampton was led by Dr Ben Maher, consultant interventional radiologist and advanced endoscopist, and a member of the PLANETS Cancer Charity clinical team.
He said: “This treatment allows us to deliver high dose of radiation directly into the tumour in a highly targeted way, while minimising the impact on surrounding healthy tissue.
“Being able to offer this treatment in the UK is an important step forward for patients with locally advanced pancreatic cancer who have limited options.”
The team had previously taken part in clinical trials evaluating the treatment – and this latest milestone marks the transition from research use to commercial availability in the UK.
PLANETS welcomed the development, highlighting the importance of access to innovative, localised therapies for patients with complex cancers.
The charity supports research and new treatment approaches for pancreatic, liver, colorectal, abdominal and neuroendocrine cancers, and works closely with specialist clinical teams in Southampton.
Layla Stephen, director of strategy and finance for PLANETS, said: “The successful delivery of OncoSil in Southampton demonstrates the role of specialist centres in bringing new technologies into clinical practice and expanding options for patients with difficult-to-treat cancers.
“We have supported the clinical team and worked with OncoSil Medical through the clinical trial and then to help bring this treatment to the UK. It is great to have it available privately initially, but our long-term hope is to see it made available via the NHS.”
Further information about the treatment and interventional oncology approaches supported by PLANETS Cancer Charity can be found at https://planetscharity.org/interventional-oncology/.
READ ABOUT HOW FUNDS ARE USED
Subscribe to our Newsletter
Get informed about the latest news straight to your inbox
